Current status and clinical usefulness of genomic panel testing using PleSSision-160 in resectable esophageal squamous cell carcinoma
This study is the first to investigate postoperative survival and chemotherapy resistance based on genomic panel testing using PleSSision-160 for resectable ESCC. The findings suggested that high CNA status was a risk factor for long-term survival. Compared to previous genomic sequencing studies in ESCC, further investigation using PleSSision-160 appears to be a promising approach.
Authors
- Kazumasa Fukuda (ORCID: https://orcid.org/0000-0001-6126-6118)
- Rieko Nakamura (ORCID: https://orcid.org/0000-0003-0947-6358)
- Hirofumi Kawakubo (ORCID: https://orcid.org/0000-0002-4929-5482)
- Kazuaki Matsui (ORCID: https://orcid.org/0000-0002-6098-5257)
- Eriko Aimono (ORCID: https://orcid.org/0000-0002-2749-654X)
- Hiroshi Nishihara (ORCID: https://orcid.org/0000-0002-5460-8703)
- Kohei Nakamura (ORCID: https://orcid.org/0000-0002-5162-7132)
- Satoru Matsuda (ORCID: https://orcid.org/0000-0001-8441-2755)
- Yuko Kitagawa (ORCID: https://orcid.org/0000-0002-0271-5670)
Institutions
- Keio University (JP)
- Keio University Hospital (JP)
Publication Details
- Journal
- European Journal of Surgical Oncology
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1016/j.ejso.2025.110481
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00